Gensight Biologics Current Valuation vs. Gross Profit
| SIGHT Stock | EUR 0.31 0.01 3.13% |
For Gensight Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Gensight Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Gensight Biologics SA utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Gensight Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Gensight Biologics SA over time as well as its relative position and ranking within its peers.
Gensight |
Gensight Biologics Gross Profit vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Gensight Biologics's current stock value. Our valuation model uses many indicators to compare Gensight Biologics value to that of its competitors to determine the firm's financial worth. Gensight Biologics SA is currently regarded number one company in current valuation category among its peers. It also is currently regarded as top stock in gross profit category among its peers fabricating about 0.05 of Gross Profit per Current Valuation. The ratio of Current Valuation to Gross Profit for Gensight Biologics SA is roughly 19.48 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Gensight Biologics' earnings, one of the primary drivers of an investment's value.Gensight Current Valuation vs. Competition
Gensight Biologics SA is currently regarded number one company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 562.02 Million. Gensight Biologics totals roughly 150.19 Million in current valuation claiming about 27% of equities under Health Care industry.
Gensight Gross Profit vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Gensight Biologics |
| = | 150.19 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gensight Biologics |
| = | 7.71 M |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Gensight Gross Profit Comparison
Gensight Biologics is currently under evaluation in gross profit category among its peers.
Gensight Biologics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Gensight Biologics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Gensight Biologics will eventually generate negative long term returns. The profitability progress is the general direction of Gensight Biologics' change in net profit over the period of time. It can combine multiple indicators of Gensight Biologics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France. GENSIGHT BIOLOGICS is traded on Paris Stock Exchange in France.
Gensight Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Gensight Biologics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Gensight Biologics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Gensight Biologics' important profitability drivers and their relationship over time.
Use Gensight Biologics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Gensight Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Gensight Biologics will appreciate offsetting losses from the drop in the long position's value.Gensight Biologics Pair Trading
Gensight Biologics SA Pair Trading Analysis
The ability to find closely correlated positions to Gensight Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Gensight Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Gensight Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Gensight Biologics SA to buy it.
The correlation of Gensight Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Gensight Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Gensight Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Gensight Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Gensight Biologics position
In addition to having Gensight Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Entertainment Thematic Idea Now
Entertainment
Companies from entertainment industry including show business, news and media. The Entertainment theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Entertainment Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Gensight Stock Analysis
When running Gensight Biologics' price analysis, check to measure Gensight Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gensight Biologics is operating at the current time. Most of Gensight Biologics' value examination focuses on studying past and present price action to predict the probability of Gensight Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gensight Biologics' price. Additionally, you may evaluate how the addition of Gensight Biologics to your portfolios can decrease your overall portfolio volatility.